MedPath
EMA Product

Emselex

Product approved by European Medicines Agency (EU)

Basic Information

Emselex

Regulatory Information

EMEA/H/C/000554

Authorised

October 22, 2004

July 29, 2004

27

October 27, 2023

Company Information

Austria

Taborstrasse 1 1020 Vienna

pharmaand GmbH

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Emselex. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Emselex.

© Copyright 2025. All Rights Reserved by MedPath